Summary:
Incannex Healthcare has established an Obstructive Sleep Apnea Clinical Advisory Board to support the development of IHL-42X, its investigational oral therapy for sleep apnea. The newly formed board includes Alison Wimms, PhD, who will represent ResMed. IHL-42X, a fixed-dose combination of acetazolamide and dronabinol, is currently in a global phase 2/3 clinical trial (RePOSA), targeting sleep apnea patients who are non-compliant, intolerant, or naïve to positive airway pressure therapy. A top-line readout from the U.S. phase 2 portion is expected in the first half of 2025, with phase 3 expansion planned for the UK and EU.
Key Takeaways:
- Incannex Appoints Alison Wimms to Advisory Board – Wimms, representing ResMed, joins the newly formed board to provide guidance on IHL-42X’s clinical development.
- IHL-42X Targets PAP-Intolerant Patients – The investigational drug is being studied in global phase 2/3 trials for individuals who cannot tolerate or comply with CPAP therapy.
- Phase 2 Data Expected in 2025 – The U.S. phase 2 portion of the RePOSA trial will report top-line results in the first half of 2025, with phase 3 expansion planned in the UK and EU.
Clinical-stage biopharmaceutical company Incannex Healthcare Inc, developing IHL-42X for the treatment of sleep apnea, announced the appointment of Alison Wimms, PhD, as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed.
Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Wimms holds a doctor of philosophy in medicine and master of medicine (sleep medicine) and bachelor of science degrees from the University of Sydney.
“Incannex’s newly formed clinical advisory board and the appointment of Dr Wimms underscore our continued dedication to innovation in the field of OSA and transforming patient treatment outcomes,” says Joel Latham, Incannex’s president and chief executive officer, in a release. “We are thrilled to welcome Dr Wimm’s expertise to our IHL-42X clinical advisory board. This marks an exciting step in fostering collaboration as we advance our global phase 2/3 RePOSA clinical study in OSA.”
Advancing IHL-42X for OSA
IHL-42X, an oral fixed-dose combination of acetazolamide and dronabinol, is currently in phase 2/3 clinical studies for the treatment of OSA. Designed to act synergistically, IHL-42X targets two different physiological pathways associated with the intermittent hypoxia and hypercapnia that characterize OSA.
In a prior Australian phase 2 clinical trial, IHL-42X was shown to reduce the apnea-hypopnea index (AHI) in all dosage strengths, with the lowest dose reducing AHI by an average of 51% relative to baseline. RePOSA, a global phase 2/3 clinical trial is underway, evaluating IHL-42X in individuals with OSA who are either non-compliant, intolerant, or naïve to positive airway pressure devices, including CPAP, with the phase 2 portion conducted in the United States.
The expanded phase 3 portion will also include sites in the United Kingdom and European Union. A top-line readout from the US phase 2 portion is anticipated in the first half of 2025.
“I am excited to join Incannex’s OSA Clinical Advisory Board. I look forward to advising on IHL-42X late-stage clinical development,” says Wimms in a release.
ID 23271342 © Springdt313 | Dreamstime.com
